Search results
UK cancer care lagging 20 years behind Europe
The Telegraph via Yahoo News· 3 days agoAn NHS spokesman said: “The NHS is seeing and treating record numbers of people for cancer, with more people diagnosed at an earlier stage than ever...
UK cancer survival ‘stuck in the noughties and trails behind other countries’
Press Association News via AOL· 3 days agoAn NHS spokesman said: “The NHS is seeing and treating record numbers of people for cancer, with...
Father and son's powerful message after both diagnosed with incurable cancer
Daily Express· 6 days agoA father and son believe they have been “brought closer together” after they received the same...
15 Life-Altering Moments In The Lives Of Cancer Survivors That Will Give You A New Perspective On...
BuzzFeed via Yahoo News· 2 days agoAnton Dobrea / Getty Images 9."I am 78 years old and at the age of 70, I was diagnosed with prostate...
AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer
Zacks via Yahoo Finance· 2 days agoThe European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for...
Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?
Zacks via Yahoo Finance· 4 days agoImage Source: Zacks...2025 has remained stable for the past 30 days. Revenues for fiscal 2024 and...
AI Enhances Readability of Cancer Information for Patients
Medscape· 5 days agoChatGPT improved the readability of cancer-related information on patient-facing websites, without...
FDA Expands Orphan Drug Designation for SurVaxM, I | Newswise
Newswise· 1 day agoThe U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive & ...
Structural basis of tolvaptan binding to the vasopressin V2 receptor - Acta Pharmacologica Sinica
Nature· 2 days agoThe vasopressin V2 receptor (V2R) is a validated therapeutic target for autosomal dominant polycystic kidney disease (ADPKD), with tolvaptan being the first FDA-approved antagonist. Herein, ...
The 10 Best Performing Stocks So Far In 2024
Forbes· 1 day agoThe stocks have been on a tear with year-to-date gains ranging from 387% to more than a jaw-dropping 1,100% (as of June 14’s market close). The stock market has been buoyant in 2024, debunking ...
